Gene Linked to Breast and Ovarian Cancer

Two of the most common forms of cancer for women are breast cancer and ovarian cancer. According to recent industry article mutations found in a gene known as PPM 1D are linked with an increased risk of breast and ovarian cancer which may be representative of a new cancer-causing process. Discovery was a result of a new study published in the Journal Nature which was conducted by a team of Researchers from the Institute of Cancer Research, London. Women with the PPM 1D mutations have a one in five chance of developing either breast or ovarian cancer. This is double the risk of breast cancer and more than 10 times the risk of ovarian cancer for women in the general population. A previous study discovered that mutations in the gene known as RAD 51C are linked with a 60 to 80% increased risk for breast cancer and a 20 to 40% risk for ovarian cancer. According to the researchers, this newly discovered research suggests that genetic testing and targeted revenge and for cancer could be a requirement, especially for ovarian cancer due to the fact that it is usually detected at a very late stage. PPM 1D appeared to be present and in entirely dissimilar way when compared to other genes that are linked with increased risk of ovarian and breast cancer including BRCA1 and BRCA2. It is the hope of researchers that women who have the genetic information detailing their risk for ovarian or breast cancer could make proactive decisions concerning steps that they could take to reduce their chances of developing either cancer. Breast cancer is a devastating diagnosis not only for the patient before her family and support system as well. Dr. Seify consults with patients who are newly diagnosed with breast cancer and helps them to understand their options related to breast reconstruction surgery. When at all possible, Dr. Seify will work with the entire team of doctors who were treating the patient. This could include the oncologist, radiologist, general surgeon as well as primary care physician. It is important for patients to understand the implications of their choices of not only which breast reconstruction method to choose but also when that choice should be made. Dr. Seify encourages patients who are reviewing the available options following breast cancer diagnosis to contact his office and schedule a consultation.

NewportPlastic